Navigation Links
A miR boost enables acute leukemia cells to mature
Date:4/3/2009

COLUMBUS, Ohio A new study by Ohio State University cancer researchers shows that boosting the level of a molecule called miR-29b in acute myeloid leukemia (AML) cells can reverse gene changes that trap the cells in an immature, fast growing state of development.

The study discovered how the miR reactivates silenced genes, which enables the leukemic cells to differentiate and mature, important steps that precede their death. The findings suggest that miR-29b could be a potent treatment for AML.

The molecule blocks the action of three enzymes, all of which add small chemical units called methyl groups to genes. The addition of the units locks genes down tight and takes them out of action.

By blocking the enzymes, the miR removes the methyl groups from genes, a process called demethylation, which then reactivates them.

The study is reported online in the journal Blood.

"We show that miR-29b is a powerful demethylating agent and provides a rationale for developing this molecule as a possible drug for the treatment of AML, alone or in combination with other agents," says first author Dr. Ramiro Garzon, a hematologist-oncologist and assistant professor of internal medicine at the Ohio State University Comprehensive Cancer Center-James Cancer Hospital and Solove Research Institute.

Garzon notes that the miR might prove to be more potent than current demethylating agents, which block only one of the three enzymes inhibited by miR-29b. "The action of miR-29b is more complete," he says.

Earlier research by the same investigators using lung cancer cells showed that miR-29b targets two enzymes, DNMT3A and DNMT3B, that both add the chemical units (methyl groups) to genes.

When the researchers raised the level of miR-29b in leukemic cells, the amount of a third enzyme, called DNMT1, fell.

"We discovered that this miR blocks DNMT1 also, but indirectly," Garzon says.

The miR, it turns out, targets another protein called Sp1 that boosts production of the DNMT1 protein.

Thus, low levels of the miR may result in lots of Sp1 protein and of DNMT1, which busily adds the chemical units that silences genes. High levels of the miR, on the other hand, may keep the amount of Sp1 low, so there is little DNMT1 and much less gene silencing.

"Our paper explains why this miR is a powerful demethylating agent," Garzon says. "It shows that putting this miR back into leukemia cell lines and leukemia cells from patients causes a drop in global DNA methylation and reactivates protective tumor suppressor genes, which allows the cells to differentiate and mature."


'/>"/>

Contact: Darrell E. Ward
Darrell.Ward@osumc.edu
614-293-3737
Ohio State University Medical Center
Source:Eurekalert  

Related biology news :

1. Therapeutic cloning gets a boost with new research findings
2. Major NSF grant boosts UNH research on hormonal genomics
3. New MegaMatcher Accelerator Boosts Speed for High-Volume Biometric Identification and Database Duplicate Searching
4. High CO2 boosts plant respiration, potentially affecting climate and crops
5. Research project to boost European fish farming
6. A little wine boosts omega-3 in the body: Researchers find a novel mechanism for a healthier heart
7. Tropical forest carbon monitoring gets big boost
8. Shrimp trawling may boost mercury in red snapper, study suggests
9. Supercomputer provides massive computational boost to biomedical research at TGen
10. Boost from McGill, Gates Foundation helps Africans control pharma research
11. Diabetes researcher gets $5M boost
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
A miR boost enables acute leukemia cells to mature
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology: